FINWIRES · TerminalLIVE
FINWIRES

Vertiv's View on Timing Shifts in Q2 Indicate Potential Recovery in Q3, UBS Says

By

Vertiv (VRT) management called out "timing shifts" in Q2 related to supply chain congestion, which could imply that growth is expected to meaningfully recover in Q3, UBS said in a Wednesday research report.

Some timing issues have worked against the company this quarter, which will weigh on the stock, but estimates are still expected to move higher, according to the note.

The stock faces further pressure from a Q2 revenue miss despite in-line underlying operating profit, as growth remains critical to the company's valuation outlook, analysts wrote.

The brokerage said it reiterated its buy rating on the stock and price target of $370 per share.

Price: $227.03, Change: $+3.99, Percent Change: +1.79%

Related Articles

Wire

Houlihan Lokey Fiscal Q1 Adjusted Earnings, Revenue Fall; Shares Drop After Hours

Houlihan Lokey (HLI) reported fiscal Q1 adjusted earnings late Wednesday of $1.35 per diluted share, down from $2.14 a year earlier.Analysts polled by FactSet expected $1.64.Revenue in the three months ended June 30 fell to $511 million from $605 million a year earlier.Analysts expected $602.4 million.Houlihan Lokey shares fell 6.6% in after-hours trading.

$HLI
Wire

Four Corners Property Trust Q2 AFFO, Revenue Rise

Four Corners Property Trust (FCPT) reported Q2 adjusted funds from operations late Wednesday of $0.45 per diluted share, up from $0.44 a year earlier.Analysts polled by FactSet expected $0.45.Revenue in the quarter ended June 30 rose to $78.4 million from $72.8 million a year earlier.Four analysts expected $79 million.The company's shares rose 2% in after-hours trading.

$FCPT
Wire

Corcept Therapeutics Q2 Earnings, Revenue Rise; Shares Jump After Hours

Corcept Therapeutics (CORT) reported Q2 earnings late Wednesday of $0.36 per diluted share, up from $0.29 a year earlier.Analysts polled by FactSet expected $0.02.Revenue for the three months ended June 30 rose to $256.1 million from $194.4 million a year earlier.Analysts expected $221.1 million.The company boosted full-year revenue guidance to $1.1 billion to $1.2 billion from the prior forecast of $950 million to $1.05 billion.Analysts project $999.5 million.Corcept shares jumped 18% in after-hours trading.

$CORT